tiprankstipranks
Opthea Limited Targets AMD Market with Sozinibercept
Company Announcements

Opthea Limited Targets AMD Market with Sozinibercept

Opthea Limited Sponsored ADR (OPT) has released an update.

Don't Miss our Black Friday Offers:

Opthea Limited, listed on NASDAQ and ASX, is advancing its promising treatment, Sozinibercept, which aims to improve vision for millions of patients suffering from wet age-related macular degeneration (AMD). With patents secured until 2034, Sozinibercept presents a substantial market opportunity, potentially revolutionizing a $15 billion global market by enhancing results when used with standard anti-VEGF-A therapies. The company anticipates pivotal trial data in 2025 and is preparing for the potential commercialization of this innovative product.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyOpthea appoints Kathy Connell to board of directors
TipRanks Auto-Generated NewsdeskOpthea Limited Strengthens Leadership and Advances AMD Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App